tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

VRDN Stock Latest News

Viridian Therapeutics: Promising Future with Strategic Trials and Financial Stability
RatingsViridian Therapeutics: Promising Future with Strategic Trials and Financial Stability
10h ago
VRDN
Viridian Therapeutics reports Q3 EPS (34c), consensus (94c)
PremiumThe Fly
Viridian Therapeutics reports Q3 EPS (34c), consensus (94c)
16h ago
VRDN
Viridian Therapeutics: Promising Future with Strategic Advancements and Financial Backing
PremiumRatings
Viridian Therapeutics: Promising Future with Strategic Advancements and Financial Backing
2d ago
VRDN
Viridian Therapeutics: Promising Prospects with Innovative TED Treatments and Financial Stability Justify Buy Rating
PremiumRatings
Viridian Therapeutics: Promising Prospects with Innovative TED Treatments and Financial Stability Justify Buy Rating
2d ago
VRDN
Viridian Therapeutics submits BLA to the FDA for veligrotug
PremiumThe Fly
Viridian Therapeutics submits BLA to the FDA for veligrotug
3d ago
VRDN
Viridian Therapeutics’ Promising Phase 3 Trial for Thyroid Eye Disease
PremiumCompany AnnouncementsViridian Therapeutics’ Promising Phase 3 Trial for Thyroid Eye Disease
9d ago
VRDN
Viridian Therapeutics Advances VRDN-003 Study for Thyroid Eye Disease
Premium
Company Announcements
Viridian Therapeutics Advances VRDN-003 Study for Thyroid Eye Disease
9d ago
VRDN
Strategic Financial Maneuvers and Key Milestones Position Viridian Therapeutics for Growth: A Buy Rating by Laura Chico
Premium
Ratings
Strategic Financial Maneuvers and Key Milestones Position Viridian Therapeutics for Growth: A Buy Rating by Laura Chico
9d ago
VRDN
Viridian Therapeutics Announces Stock Sale Agreement
PremiumCompany Announcements
Viridian Therapeutics Announces Stock Sale Agreement
14d ago
8K
VRDN
Viridian Therapeutics 11.425M share Spot Secondary priced at $22.00
PremiumThe Fly
Viridian Therapeutics 11.425M share Spot Secondary priced at $22.00
15d ago
VRDN
Viridian Therapeutics announces common stock and preferred stock offering
PremiumThe Fly
Viridian Therapeutics announces common stock and preferred stock offering
15d ago
VRDN
Viridian Therapeutics price target raised to $36 from $32 at Oppenheimer
PremiumThe Fly
Viridian Therapeutics price target raised to $36 from $32 at Oppenheimer
16d ago
VRDN
3 Best Stocks to Buy Now, 10/21/2025, According to Top Analysts
PremiumMarket News3 Best Stocks to Buy Now, 10/21/2025, According to Top Analysts
16d ago
DSP
NOW
Viridian Therapeutics Secures $300M Deal with DRI Healthcare
Premium
Company Announcements
Viridian Therapeutics Secures $300M Deal with DRI Healthcare
16d ago
8K
VRDN
Viridian Therapeutics: Strategic Financial Agreement and Promising Product Launches Drive Buy Rating
Premium
Ratings
Viridian Therapeutics: Strategic Financial Agreement and Promising Product Launches Drive Buy Rating
17d ago
VRDN
Viridian Therapeutics: Strategic Royalty Financing and Promising TED Treatment Pipeline Justify Buy Rating
PremiumRatings
Viridian Therapeutics: Strategic Royalty Financing and Promising TED Treatment Pipeline Justify Buy Rating
17d ago
VRDN
Viridian Therapeutics enters royalty financing agreement with DRI Healthcare
PremiumThe Fly
Viridian Therapeutics enters royalty financing agreement with DRI Healthcare
17d ago
VRDN
Viridian Therapeutics: Strong Buy Rating Backed by Superior Efficacy and Strategic Advancements in TED Market
PremiumRatings
Viridian Therapeutics: Strong Buy Rating Backed by Superior Efficacy and Strategic Advancements in TED Market
19d ago
VRDN
Underwhelming Roche data helps Veridian’s position in TED, says Jefferies
PremiumThe Fly
Underwhelming Roche data helps Veridian’s position in TED, says Jefferies
19d ago
CHRO
VRDN
Viridian Therapeutics Positioned for Success Amid Competitive Challenges in TED Market
PremiumRatingsViridian Therapeutics Positioned for Success Amid Competitive Challenges in TED Market
20d ago
VRDN
Buy Rating Affirmed for Viridian Therapeutics Amid Promising Developments in Thyroid Eye Disease Treatment
Premium
Ratings
Buy Rating Affirmed for Viridian Therapeutics Amid Promising Developments in Thyroid Eye Disease Treatment
20d ago
VRDN
Viridian Therapeutics’ Veligrotug Outperforms Roche’s Satralizumab in TED Treatment, Supporting Buy Rating
Premium
Ratings
Viridian Therapeutics’ Veligrotug Outperforms Roche’s Satralizumab in TED Treatment, Supporting Buy Rating
20d ago
VRDN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >